20-F: CordovaCann Reports Increased Loss Amid Asset Sales & Control Weaknesses

CordovaCann Corp. reported a widened net loss for fiscal year 2025 despite revenue growth, driven by significant asset impairments and ongoing operational challenges, while also disclosing ineffective internal controls.

Summary

• Net loss for fiscal year 2025 increased to $2,454,615, up from $1,275,056 in 2024.
• Revenue grew by 3% to $14,249,111 in 2025, primarily due to a 5% increase in same-store sales in Ontario retail locations, offsetting declines in Washington and Manitoba operations.
• Total assets decreased significantly to $6,406,003 in 2025 from $9,553,495 in 2024, largely due to the sale of land and building in Washington, USA, and impairment charges in Oregon, USA.
• The company recorded substantial impairment charges in 2025, including $860,816 for property and equipment and $828,370 for right-of-use assets, primarily related to Oregon and Washington operations.
• Working capital deficiency remained high at $7,413,677 as of June 30, 2025.
• Cash provided by operating activities decreased to $1,140,200 in 2025 from $1,493,629 in 2024.
• Cash provided by investing activities was $1,548,933 in 2025, mainly from the sale of the Washington land and building for gross proceeds of $1,705,375 (US $1,250,000).
• Cash used in financing activities increased to $2,510,884 in 2025, primarily for repayments of mortgage payable and promissory notes, and dividends to non-controlling interest shareholders.
• Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, citing material weaknesses including lack of segregation of duties and reliance on independent consultants.
• The CEO and CFO agreed to a 50% decrease in their compensation effective January 1, 2025.
• Several promissory notes are in default and due on demand.
• The company is involved in two legal proceedings, one in California for injunctive relief and one in Ontario with a claim of approximately $1,900,000 against the company, to which the company has filed a counterclaim for $800,000.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the significant increase in net loss, worsening shareholder deficiency, and explicit disclosure of material weaknesses in internal controls, all contributing to substantial doubt about the company's going concern ability, despite modest revenue growth.

Positives

• Revenue increased by 3% to $14,249,111 in fiscal year 2025, driven by strong same-store sales growth of approximately 5% in Ontario retail locations.
• Gross margin increased to $4,166,208 in 2025 from $4,076,912 in 2024, with the gross margin percentage remaining consistent, partly due to the closure of unprofitable Western Canada stores.
• Operating expenses decreased to $4,371,591 in 2025 from $4,718,872 in 2024, reflecting reduced salaries and wages from Washington operations and a decrease in consulting fees.
• The CEO and CFO voluntarily reduced their compensation by 50% starting January 1, 2025, demonstrating a commitment to cost control.
• The sale of land and building in Washington, USA, generated gross proceeds of $1,705,375 (US $1,250,000) and a gain on disposition of $203,824, which was used to repay debt.
• Cash provided by operating activities remained positive at $1,140,200 in 2025.
• Cash provided by investing activities was positive at $1,548,933 in 2025, largely due to the asset sale.

Negatives

• Net loss for the year ended June 30, 2025, significantly widened to $2,454,615 from $1,275,056 in the prior year.
• The company has a substantial working capital deficiency of $7,413,677 as of June 30, 2025, indicating significant short-term liquidity challenges.
• Total assets decreased by over $3 million from $9,553,495 in 2024 to $6,406,003 in 2025, primarily due to asset sales and impairment charges.
• Shareholders' equity (deficiency) worsened to $(5,205,000) in 2025 from $(2,597,013) in 2024.
• Significant impairment charges were recorded in 2025: $860,816 for property and equipment and $828,370 for right-of-use assets, reflecting reduced operational activity in Oregon and Washington.
• Cash used in financing activities increased substantially to $2,510,884 in 2025 from $1,096,506 in 2024, indicating a higher reliance on debt repayments and non-controlling interest dividends.
• Several promissory notes are in default and due on demand, including amounts owed to the Chief Executive Officer and Chairman.
• The company faces two active legal proceedings, including a claim of approximately $1,900,000 against it in Ontario.
• Management concluded that disclosure controls and procedures were not effective, identifying material weaknesses such as lack of segregation of duties and reliance on independent consultants.
• The company has a history of recurring losses and a net capital deficiency, raising substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and a net capital deficiency of $5,805,888 as of June 30, 2025.
• Operations in the U.S. cannabis industry remain illegal under federal law, exposing the company to enforcement risks despite state-level compliance.
• Difficulty for cannabis businesses to open and maintain bank accounts due to federal illegality and anti-money laundering statutes, potentially affecting financial transactions.
• U.S. cannabis-related proceeds are considered proceeds of crime under federal law, restricting the ability to declare dividends or repatriate funds to Canada.
• Investments in the U.S. cannabis market may face increased scrutiny from Canadian regulators, stock exchanges, and clearing agencies, potentially leading to restrictions.
• Evolving and inconsistent laws, regulations, and guidelines in the cannabis industry could lead to significant compliance costs, operational changes, or material liabilities.
• Risk of being taxed as a U.S. corporation for federal income tax purposes under Section 7874, leading to double taxation (Canada and U.S.) and potential U.S. withholding tax on distributions.
• Risk of being classified as a Passive Foreign Investment Company (PFIC), leading to adverse U.S. tax consequences for U.S. shareholders.
• Risk of being deemed an investment company under the United States Investment Company Act of 1940, requiring burdensome compliance and restricting activities.
• Common shares are classified as penny stock, which may adversely affect liquidity and trading activity due to extensive broker-dealer disclosure requirements.
• Continued development requires additional financing, with no guarantee of availability or acceptable terms, potentially leading to significant shareholder dilution or restrictive debt covenants.
• Investments in entities with no significant operating cash flow or revenue carry risks of business failure.
• Reliance on third-party investments means cash flows are dependent on their activities, which may not align with the company's interests or could face operational difficulties.
• Investments in private companies or illiquid securities may restrict the ability to sell them timely or at acceptable prices.
• The cannabis industry is highly dependent on consumer perception, and adverse publicity could materially affect demand and business.
• The company has operated at a loss and may continue to do so, making it difficult for investors to evaluate operations and prospects.
• Intense competition for financing and investment opportunities from companies with greater financial resources, potentially affecting strategic agreements, talent retention, and market share.
• Exposure to significant currency exchange fluctuations between U.S. and Canadian dollars, which could materially affect financial results.
• Risks associated with integrating new operations, unforeseen liabilities, diversion of resources, inability to generate sufficient revenue, and potential loss of relationships from strategic transactions.
• No guarantee of enforcing interests in investments if they face bankruptcy or similar events, potentially leading to loss of payments.
• No assurance that research and market development activities will prove profitable or that resulting markets/products will be commercially viable, given the early stage of the medical and recreational cannabis industry.
• Success depends on senior management; loss of key individuals or inability to attract qualified persons could adversely affect business execution.
• Inability to obtain or maintain necessary licenses, permits, authorizations, or accreditations, or to comply with regulations, could result in restrictions on an investment's ability to operate.
• Exposure to litigation, complaints, and enforcement actions that could consume considerable financial and other corporate resources and negatively impact financial performance and reputation.
• Inherent risk of product liability claims for ingested products, potentially leading to increased costs, adverse effects on reputation, and material adverse effects on financial condition.
• Dependence on a number of key inputs (raw materials, electricity, water) and their related costs; any significant interruption or negative change in supply chain could materially impact operations.
• The publicly-traded stock price of the common shares may be subject to market trends and volatility, potentially affecting the value of the shares.
• Significant growth in personnel may place a strain upon management systems and resources, potentially leading to inadequate support for future operations.
• No assurance that an active and liquid market for the common shares will develop or be maintained, potentially limiting liquidity and affecting the share price.
• Vulnerability to competitors developing competing technology or misappropriating intellectual property; effective future patent, copyright, and trade secret protection may be unavailable or limited.
• Currently insufficient insurance coverage; no assurance of adequate or affordable coverage in the future, or that existing coverage will be sufficient to cover claims.
• Exposure to operational risks including labor disputes, catastrophic accidents, fires, social activism, regulatory changes, and natural phenomena, which could have an adverse impact on future cash flows and financial condition.
• Ongoing legal, accounting, and other expenses related to regulatory compliance as a public company.
• As a holding company, cash flows and enhancement opportunities are dependent on the earnings and distributions of subsidiaries and investments, which are subject to operating results, laws, and contractual restrictions.
• No assurance that the company will be successful in the implementation of its business strategy.
• Potential for conflicts of interest where directors and officers are involved in other business ventures that may compete with the company's interests.
• Adverse changes or disruptions to the functionality, security, and operation of the company's retail sites or any other form of non-compliance may place retail store authorizations at risk; expansion requires regulatory approval.

Future Outlook

Management is actively examining business opportunities in the cannabis industry to enhance shareholder value, with a near-term focus on growing its retail operations in Ontario and Manitoba through new store development and strategic acquisitions. The long-term strategy involves expanding into additional legal markets globally and leveraging its low-cost infrastructure and white-label manufacturing platforms to develop and acquire niche cannabis brands and broaden distribution channels, anticipating acceleration with potential upcoming federal legalization in the U.S.

Management Comments

• Management continuously monitors all U.S. Attorney comments related to regulated medical and recreational cannabis laws to assess various risks and enforcement priorities within each jurisdiction.
• Continued funding from equity and debt issuances will provide sufficient cash flow for the company to continue as a going concern in its present form until its operations become profitable and cash flow positive, however, there can be no assurances that the Company will achieve this.
• The CEO and CFO of the Company have agreed to a 50% decrease in its compensation starting January 1, 2025 which is reflected in these results.
• Management continues to take an active approach to examining business opportunities in the cannabis industry that could enhance shareholder value.
• The Company is expecting to grow its retail operations both through development of new stores as well as looking for acquisition opportunities in strategic markets.
• The Company's management, including its Chief Executive Officer and Chief Financial Officer, does not expect that the Company's disclosure controls and procedures or internal controls will prevent all errors and all fraud.

Industry Context

StockSavvy.ai notes that CordovaCann operates within a highly dynamic and uncertain cannabis industry, particularly in the U.S. where federal illegality clashes with state-level legalization. The ongoing legislative efforts like the SAFER Banking Act and potential federal rescheduling of cannabis (from Schedule I to Schedule III) could significantly alter the operating landscape, potentially easing banking restrictions and tax burdens (e.g., 280E). However, the political uncertainty following the U.S. presidential election in November 2024 introduces a new layer of unpredictability regarding federal enforcement policy. The company's strategy of focusing on retail expansion in Canada and white-label manufacturing/niche brands in the U.S. positions it to capitalize on both established and emerging market segments, but also exposes it to the inherent regulatory and competitive risks of a nascent industry.

Comparison to Industry Standards

• The company's recurring losses and significant working capital deficiency are below industry standards for established, profitable cannabis operators, which typically demonstrate positive cash flow and stronger balance sheets.
• The reported ineffective internal controls, particularly the lack of segregation of duties and reliance on consultants, fall short of best practices for publicly traded companies, especially those operating in a highly regulated industry like cannabis.
• While revenue growth of 3% is positive, it is modest compared to some high-growth cannabis companies that have achieved double-digit or triple-digit growth in expanding markets.
• The significant impairment charges on assets in Oregon and Washington suggest underperforming or divested assets, which contrasts with companies successfully expanding and optimizing their asset base in key cannabis markets.
• The company's three-pronged strategy (retail, white-label, niche brands) is a common approach in the fragmented cannabis industry, similar to multi-state operators (MSOs) like Curaleaf or Green Thumb Industries, but CordovaCann's financial performance indicates challenges in execution or market penetration compared to these larger, more established players.
• The reliance on equity and debt issuances for funding, coupled with outstanding promissory notes in default, indicates a weaker financial position compared to industry leaders who can fund growth through robust operating cash flows or more favorable financing terms.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in a complaint in Orange County Superior Court of California for injunctive relief, related to a guaranteed loan for lab equipment ($251,793) where the other defendants allegedly failed to pay off the loan and converted the equipment. No claim for damages against the company currently, and the company has not been served.
• A lawsuit was filed in Ontario Superior Court of Justice on September 26, 2024, by 10330698 Canada Inc. claiming approximately $1,900,000. The company filed a statement of defense denying allegations and a counterclaim for $800,000 for breach of contract and misrepresentation.

Related Party Transactions

• Expensed $486,000 in fees payable to officers and directors of the company and a related corporation during the year ended June 30, 2025.
• As of June 30, 2025, fees payable to officers and directors amounted to $3,682,687.
• Included in the 2023 Demand Notes are principal of $136,430 (US $100,000) and accrued interest of $20,465 (US $15,000) owed to the Chief Executive Officer and Chairman, which remain outstanding and are in default.

Stakeholder Impact

• Shareholders face significant dilution risk if additional equity financing is pursued. The substantial net loss and worsening equity deficiency negatively impact shareholder value. The penny stock classification may limit liquidity.
• Creditors face increased credit risk due to promissory notes in default and the overall going concern uncertainty.
• Employees may experience potential instability or limited growth in permanent employment opportunities outside of retail stores, as indicated by reduced salaries and wages in Washington operations and reliance on consultants.
• Customers could face potential impacts on product availability or quality if operational challenges in Oregon and Washington persist or if regulatory issues disrupt supply chains.
• Management, including the CEO and CFO, voluntarily reduced compensation, indicating a shared burden in financial challenges, but also potential pressure.

Next Steps

• Continue to grow retail operations in Canada (Ontario and Manitoba) through new store development and strategic acquisitions.
• Seek to enter additional key legal cannabis markets not currently served.
• Expand operations in existing markets where the company already has a presence.
• Develop various end products for distribution in current markets.
• Service other brands and intellectual property owners with processing and manufacturing platforms.
• Broaden distribution channels.
• Organically build and acquire cannabis producers, processors, and retailers globally.
• Address identified material weaknesses in internal controls over financial reporting, including implementing adequate segregation of duties as the company grows.
• Defend against the legal complaint in Orange County Superior Court of California.
• Defend against the lawsuit in Ontario Superior Court of Justice and pursue the $800,000 counterclaim.
• Review the Audit Committee Charter annually and submit recommended changes to the Board for approval.

Key Dates

Recommendation

The company's significant increase in net loss, worsening working capital and shareholder deficiency, and explicit disclosure of substantial doubt about its ability to continue as a going concern present a highly unfavorable financial outlook. Material weaknesses in internal controls and multiple legal proceedings further compound the risks. Despite modest revenue growth, the overall financial health and operational stability are severely compromised, making the stock a strong sell for seasoned investors.

Keywords

Cannabis, Retail, White Label Manufacturing, Niche Brands, SEC Filing, Form 20-F, Financial Report, CordovaCann Corp, CDVA, LVRLF, Going Concern, Net Loss, Revenue Growth, Asset Impairment, Internal Controls, Regulatory Risk, Liquidity, Canada, United States, Oregon, Washington, Ontario, Manitoba, Promissory Notes, Legal Proceedings, Management Compensation, Shareholders' Equity, Capital Deficiency, Cannabis Industry, Financial Reporting, Corporate Governance